It comes at a tricky time for Novavax, with CEO John Jacobs promising in August that the company would “unveil a new and expanded clinical pipeline by the end of this year.” Ahead of this ...
Novavax has been gearing up to launch a phase 3 trial of what may result in an important product: A combined flu and coronavirus vaccine. But the company now faces a roadblock, saying regulators ...
Novavax (NVAX) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.
The company’s CEO, Vlad Tenev, announced the launch of futures trading and index options trading at the HOOD Summit 2024 in Miami, Florida. Novavax Inc. NVAX Novavax’s stock took a hit ...
Novavax Inc.’s stock tumbled 19% early Wednesday after the company said the Food and Drug Administration has placed a clinical hold on its COVID-19-and-flu combination and stand-alone flu ...
The market expects Novavax (NVAX) to deliver a year-over-year increase in earnings on lower revenues when it reports results for the quarter ended September 2024. This widely-known consensus ...
Novavax said a participant enrolled in a mid-stage study of the combination vaccine last month reported symptoms of motor neuropathy, or damage to the nerve cells that control muscles or movement.
Results that may be inaccessible to you are currently showing.